Hydroxy, Bonded Directly To Carbon, Attached Directly Or Indirectly To The Acyclic Carbon Or Chain By Acyclic Nonionic Bonding (e.g., Beta Hydroxy Phenethylamines, Etc.) Patents (Class 514/653)
  • Patent number: 10265373
    Abstract: The present invention relates to the use of one or more compounds selected from the following classes of biologically active agents: an a-adrenergic antagonist, an anthelmintic agent, an antifungal agent, an antimalarial agent, an antineoplastic agent, an antipsychotic agent, an antioxidant, a vasodilator and/or a vitamin, or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection and in particular for killing multiplying, non-multiplying and/or clinically latent microorganisms associated with such an infection.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: April 23, 2019
    Assignee: HELPERBY THERAPEUTICS LIMITED
    Inventors: Yanmin Hu, Anthony R M Coates
  • Patent number: 10251868
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: April 9, 2019
    Assignee: NOVARTIS AG
    Inventors: Jun Cao, Bernhard Erb, Robin Alec Fairhurst, Arnaud Grandeury, Shinji Hatakeyama, Magdalena Koziczak-Holbro, Xinzhong Lai, Philipp Lustenberger, Bernd Ulrich Riebesehl, Nicola Tufilli, Thomas Ullrich, Xiang Wu, Jianguang Zhou
  • Patent number: 10159657
    Abstract: The inventive subject matter is directed to compositions and methods for ready-to-inject norepinephrine compositions with improved stability. Most preferably, compositions presented herein are substantially antioxidant free and exhibit less than 10% isomerization of R-nor epinephrine and exhibit less than 5% degradation of total norepinephrine.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: December 25, 2018
    Assignee: NEVAKAR INC.
    Inventors: Vivek Yadav, Sriramya Garapati, Tushar Hingorani, Iouri V. Ilitchev, Prem Sagar Akasapu, Kumaresh Soppimath, Navneet Puri
  • Patent number: 10130592
    Abstract: Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: November 20, 2018
    Assignee: PAR PHARMACEUTICAL, INC.
    Inventors: Vinayagam Kannan, Patrick Irish, Michael Bergren
  • Patent number: 10022339
    Abstract: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes. Also disclosed are methods of treating respiratory illness through administration of a composition comprising phenylephrine, its free and addition salt forms, and mixtures thereof alone, or in combination with other pharmaceutical actives, wherein the composition has a pH of from about 2 to about 5 and is substantially free of aldehydes.
    Type: Grant
    Filed: April 21, 2006
    Date of Patent: July 17, 2018
    Assignee: The Procter & Gamble Company
    Inventors: Kelly Lee Martin, Jayant Eknath Khanolkar, Douglas William Gledhill, Susan Elaine Criss, Niranjan Ramji, Elaine Rose Costeines
  • Patent number: 9943471
    Abstract: A method for improving skin scar color matching, for example reducing scar hyperpigmentation, the method comprising administering a therapeutically effective amount of an agent, which positively modulates ?2-adrenergic receptor conformation, or receptor activity, or activation thereof, to a subject in need thereof. The subject typically is in need of improving skin scar color matching, for example reducing scar hyperpigmentation, because the subject has or is at risk of hyperpigmentation. The subject typically is selected as being at risk of hyperpigmentation on the basis of one or more of the following factors: ? the subject has previously developed hyperpigmentation of a scar ? the subject tans readily on exposure to sunshine or ultraviolet (UV) radiation, rather than burning ? the subject has a non-Caucasian racial origin ? the subject's skin color (for example in an area that is not tanned) is considered to be darker than that typical of a naturally fair-haired Caucasian person.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: April 17, 2018
    Assignee: UNIVERSITY OF LEICESTER
    Inventor: Christine Elaine Pullar
  • Patent number: 9700522
    Abstract: The present invention is directed to compositions and devices for transdermally administering vitamin B12 to a subject. In one aspect, a vitamin B12 containing composition suitable for transdermal administration is provided in the form of a shelf stable transdermal delivery patch. Such patches contain vitamin B12 combined with selected penetration enhancers and vitamin B12 stabilizers.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: July 11, 2017
    Assignee: VITA SCIENCES LLC
    Inventor: Jon Zeltman
  • Patent number: 9492405
    Abstract: This disclosure concerns the discovery of the use of fenoterol and (R,R)- and (R,S)-fenoterol analogs for the treatment of a tumor expressing a ?2-adrenergic receptor, such as a primary brain tumor, including a glioblastoma or astrocytoma expressing a ?2-adrenergic receptor. In one example, the method includes administering to a subject a therapeutically effective amount of fenoterol, a specific fenoterol analog or a combination thereof to reduce one or more symptoms associated with the tumor, thereby treating the tumor in the subject.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: November 15, 2016
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, SRI International
    Inventors: Irving W. Wainer, Michel Bernier, Lawrence Robert Toll, Lucita Arenas Jimenez
  • Patent number: 9486406
    Abstract: The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: November 8, 2016
    Assignee: Omeros Corporation
    Inventors: Gregory A. Demopulos, Hui-rong Shen, Clark E. Tedford
  • Patent number: 9388121
    Abstract: Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: July 12, 2016
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • Patent number: 9370497
    Abstract: The present invention relates generally to the field of inflammatory diseases of the peripheral nervous system. More particularly, it concerns methods for treating inflammatory diseases of the peripheral nervous system by modulating sphingosine-1-phosphate receptor activity. In one embodiment, the present invention provides a method of treating a subject with chronic inflammatory demyelinating polyneuropathy (CIDP) or other autoimmune neuropathies comprising administering to the subject an effective amount of FTY720.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: June 21, 2016
    Assignee: The University of Chicago
    Inventor: Betty C. Soliven
  • Patent number: 9364450
    Abstract: Clenbuterol or its salt for use in the treatment of autism, in particular pediatric autism. Improved contact with surroundings, better concentration, improved ability to plan a specific task, improved understanding, calming, and reduced psychomotor anxiety were observed.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: June 14, 2016
    Assignees: STOWARZYSZENIE SW. CELESTYNA, KRYSTYNA KOBEL-BUYS
    Inventor: Krystyna Kobel-Buys
  • Patent number: 9290603
    Abstract: The present invention relates to novel amides having secondary amino groups, a process for preparing them, adducts of these amines and their uses. The amides can be prepared in a simple way from readily available starting materials. They and their adducts have, in particular, a low viscosity and are suitable as constituent of polyurethane and polyurea compositions having excellent processability and high flexibility, and also as constituent of epoxy resin compositions, in particular coatings.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: March 22, 2016
    Assignee: SIKA TECHNOLOGY AG
    Inventor: Urs Burckhardt
  • Patent number: 9265754
    Abstract: Use of an S1P receptor modulator in the treatment or prevention of a disease or condition dependent on brain-derived neurotrophic factor (BDNF) expression.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: February 23, 2016
    Assignee: Novartis AG
    Inventors: Yves-Alain Barde, Graeme Bilbe, Ruben Deogracias, Rainer R. Kuhn, Tomoya Matsumoto, Anis Khusro Mir, Anna Svenja Schubart
  • Patent number: 9101576
    Abstract: The present invention relates generally to the field of inflammatory diseases of the peripheral nervous system. More particularly, it concerns methods for treating inflammatory diseases of the peripheral nervous system by modulating sphingosine-1-phosphate receptor activity. In one embodiment, the present invention provides a method of treating a subject with chronic inflammatory demyelinating polyneuropathy (CIDP) or other autoimmune neuropathies comprising administering to the subject an effective amount of FTY720.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: August 11, 2015
    Assignee: The University of Chicago
    Inventor: Betty C. Soliven
  • Publication number: 20150140137
    Abstract: Compositions and methods for alleviating an allergy condition while also reducing a drying effect of an allergy treatment composition or another anti-mucosal composition. In some embodiments and implementations, a composition may be provided comprising an allergy treatment composition comprising an antihistamine in a therapeutically effective amount for treating the allergy condition in the human having the allergy condition. The composition may further comprise an anti-drying composition comprising at least one of xylitol, erythiritol, mannitol, maltitol, tibitol, arabitol, ribose, and xylose in one or more therapeutically effective amounts for reducing nasal dryness caused by the allergy treatment composition. The composition may be delivered into at least one of the human's nose, eyes, mouth, and throat.
    Type: Application
    Filed: January 27, 2015
    Publication date: May 21, 2015
    Inventors: Alonzo H. Jones, Nathan Jones
  • Publication number: 20150141502
    Abstract: A method of inhibiting the growth of leukemic hematopoietic stem cells in a subject with leukemia is described. The method includes administering a therapeutically effective amount of a composition including a compound of formula I: I wherein R1 is independently selected from hydrogen and methyl; R2 is selected from the group consisting of 4,8-dimethyl-non-1-enyl, 4,8-dimethyl-nonyl, non-1-enyl, and nonanyl groups; X is a carboxyl, phosphonic, or sulfonic moiety, and n is an integer from 1 to 6, or a compound of Formula II: II wherein R1 is a C6-C12 alkyl or C6-C12 alkoxy group; R2 is independently selected from the group consisting of hydrogen, methoxy, and hydroxyl; and R3 is an alkyl or cycloalkyl group; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 21, 2015
    Applicant: Ohio State Innvation Foundation
    Inventors: Danilo Perrotti, Paolo Neviani
  • Publication number: 20150141520
    Abstract: Stabilized pharmaceutical compositions comprising a S1P receptor modulator as an active agent(s), process of preparation and method of using the same are provided. The present invention also relates to stabilized pharmaceutical compositions comprising fingolimod, or pharmaceutically acceptable salts, esters, hydrates and solvates thereof, process of preparation and method of using the same.
    Type: Application
    Filed: November 18, 2014
    Publication date: May 21, 2015
    Inventors: Chandrasekhar Kandi, Nagaprasad Vishnubhotla, Asif Anwar, Krishnakumar Chegonda, Sivakumaran Meenakshisunderam
  • Publication number: 20150140113
    Abstract: The present invention generally relates to dosage forms for oral administration including one or more gelling agents. In particular, the present invention is directed to gelling agent-based dosage forms that are easily administered and taken, or swallowed. The present invention is also directed to gelling agent-based dosage forms that exhibit relatively low syneresis, are thermally stable, exhibit substantially constant active ingredient concentration, and/or exhibit one or more advantageous rheological properties. In particular, the present invention is directed to such gels containing one or more omega-3 fatty acids. The gelling agent-based dosage forms of the present invention are suitable for administration of a relatively large dose of active ingredient. The gelling agent-based dosage forms of the present invention are also suitable for administration of multiple active ingredients.
    Type: Application
    Filed: March 19, 2013
    Publication date: May 21, 2015
    Applicant: PARTICLE DYNAMICS INTERNATIONAL, LLC
    Inventors: Irwin Jacobs, Stephen Gee, Paul Brady
  • Publication number: 20150132260
    Abstract: The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.
    Type: Application
    Filed: April 19, 2013
    Publication date: May 14, 2015
    Inventors: Marc Eloit, Justine Cheval, Charles Hebert, Marc Lecuit
  • Publication number: 20150133563
    Abstract: The invention is directed to methods and compositions of stabilizing phenylephrine formations. The composition has good time-dependent stability at low temperature and has no change in its outward appearance even after having been stored at least 6 months.
    Type: Application
    Filed: September 4, 2014
    Publication date: May 14, 2015
    Inventors: Patrick H. Witham, Sailaja Machiraju, Lauren Mackensie-Clark Bluett
  • Patent number: 9029421
    Abstract: The present invention provides a process for preparing a compound of formula (VI) or a salt thereof, the process comprising: (i) reacting 4-methoxyphenyl acetone with an amine of formula (VIII) under conditions of reductive amination to produce a compound of formula (II) or a salt thereof, wherein there is no isolation of an imine intermediate formed during the reductive amination; (ii) condensing the compound (II) or the acid addition salt thereof with an ?-haloketone of formula (III) to produce the compound of formula (IV); (iii) reducing the compound (IV) to a compound of formula (V); and (iv) reducing the compound (V) to the compound of formula (VI), wherein the reduction is carried out in the presence of either (1) a hydrogen donating compound in the presence of a hydrogen transfer catalyst; or (2) ammonium formate using a hydrogenation catalyst, wherein R1 and R2 are independently optionally substituted arylalkyl, and Hal is selected from chloro or bromo.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: May 12, 2015
    Assignee: Cipla Limited
    Inventors: Vaishali Vaman Haldavanekar, Mangesh Prabhu, Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan
  • Publication number: 20150126542
    Abstract: This disclosure relates to methods of increasing the metabolic lifetime of dextromethorphan administering threohydroxybupropion or a prodrug thereof to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and threohydroxybupropion or a prodrug of theohydroxybupropion are also disclosed.
    Type: Application
    Filed: November 26, 2014
    Publication date: May 7, 2015
    Inventor: Herriot Tabuteau
  • Publication number: 20150126437
    Abstract: The disclosure provides compounds useful as insect repellents, compositions comprising such repellents, and methods of repelling an arthropod using such compounds and compositions. The disclosure further provides insect traps and method for identifying ligands and cognates for biological molecules.
    Type: Application
    Filed: October 17, 2012
    Publication date: May 7, 2015
    Applicant: The Regents of the University of California
    Inventors: Anandasankar Ray, Sean Michael Boyle
  • Publication number: 20150126556
    Abstract: The invention generally relates to methods of using adrenergic receptor agonists for the treatment of skin and mucosal superficial wounds. Some of the preferred adrenergic receptor agonists include epinephrine, phenylephrine, norepinephrine, methoxamine, and mixtures thereof. Methods according to the invention are especially effective to control superficial skin and mucosal bleeding and accelerate healing time.
    Type: Application
    Filed: January 14, 2015
    Publication date: May 7, 2015
    Inventor: Roman Kelner
  • Publication number: 20150118285
    Abstract: The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized drug delivery and protection to the treatment site. The kinetics of erodability are easily adjusted by varying the number of layers and/or the components.
    Type: Application
    Filed: September 10, 2014
    Publication date: April 30, 2015
    Inventors: Gilles H. Tapolsky, David W. Osborne
  • Patent number: 9018240
    Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: April 28, 2015
    Assignee: Voom, LLC
    Inventor: Mark Silverberg
  • Publication number: 20150107589
    Abstract: A dry powder inhaler (DPI) device has a flow passage with a three-dimensional (3D) rod array. The rod array includes multiple rows each having multiple unidirectional rods. The rows are spaced apart along a primary direction of air flow and are staggered. A viewing window to the capsule chamber allows viewing of the capsule's position within the chamber which provides visual feedback of inhalation flow rate to the user during inhalation. The capsule chamber may orient the capsule parallel to a primary direction of air flow or perpendicular to a primary direction of air flow and provide capsule motion in a plane which is perpendicular to the primary direction of air flow.
    Type: Application
    Filed: April 23, 2013
    Publication date: April 23, 2015
    Inventors: Phillip Worth Longest, Michael Hindle, Yeon-Ju Son, S. R. B. Behara, Dale Farkas
  • Patent number: 9011922
    Abstract: Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes).
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: April 21, 2015
    Assignee: Revalesio Corporation
    Inventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
  • Publication number: 20150104497
    Abstract: Topical sphingosine-1-phosphate receptor agonist active agent formulations are provided. Aspects of the transdermal formulations include an amount of a sphingosine-1-phosphate receptor agonist active agent in combination with a topical delivery vehicle, e.g., a topical patch that includes an adhesive layer and a backing layer. Also provided are methods of topically delivering a therapeutically effective amount of a sphingosine-1-phosphate receptor agonist active agent to a subject, e.g., to treat a subject for a disease condition, such as an immune system disorder like multiple sclerosis, a hyperproliferative dermatological disorder, e.g., psoriasis, acne, etc. Packaged topical formulations, kits including such formulations, and methods of making such formulations are also provided.
    Type: Application
    Filed: August 29, 2014
    Publication date: April 16, 2015
    Inventors: Adchara Pongpeerapat, Bret Berner, Kensuke Murata
  • Publication number: 20150104515
    Abstract: The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion.
    Type: Application
    Filed: May 15, 2014
    Publication date: April 16, 2015
    Applicant: Massachusetts Institute of Technology
    Inventors: David A. Edwards, Robert S. Langer, Rita Vanbever, Jeffrey D. Mintzes, Jue Wang, Donghao Chen
  • Publication number: 20150094378
    Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.
    Type: Application
    Filed: May 1, 2014
    Publication date: April 2, 2015
    Applicant: Civitas Therapeutics, Inc.
    Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
  • Patent number: 8993635
    Abstract: The present invention relates to methods and feed compositions for increasing or maintaining the reproductive performance of sows. More particularly, the present invention relates to methods of increasing or maintaining the reproductive performance of sows by administering a biologically active compound during lactation, and food compositions comprising said biologically active compound for the purposes of increasing or maintaining the reproductive performance of sows. The present invention also relates to a method of increasing or maintaining ovarian function in sows.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: March 31, 2015
    Assignee: Pork CRC Ltd
    Inventor: William van Wettere
  • Publication number: 20150087620
    Abstract: The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, which has a superior peripheral blood lymphocyte decreasing action, and is useful for the treatment or prophylaxis of autoimmune diseases; prophylaxis or suppression of resistance or acute rejection or chronic rejection of transplantation of organ or tissue; treatment or prophylaxis of graft-versus-host (GvH) disease due to bone marrow transplantation; or treatment or prophylaxis of allergic diseases.
    Type: Application
    Filed: April 23, 2013
    Publication date: March 26, 2015
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Maiko Hamada, Kaoru Tashiro, Hiroshi Sakashita, Masatoshi Kiuchi, Shuzo Takeda, Kunitomo Adachi
  • Publication number: 20150087720
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial 3 to 6 days of treatment the daily dosage is raised so that in total the R-fold (R being the accumulation factor) standard daily dosage is administered and thereafter continued at the standard daily dosage or at a daily dosage lower than the standard daily dosage.
    Type: Application
    Filed: October 16, 2014
    Publication date: March 26, 2015
    Applicant: Novartis AG
    Inventors: John M. Kovarik, Silke Appel-Dingemanse
  • Patent number: 8987262
    Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroïds, interferon or vincristine, generally used for the treatment of hemangiomas.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: March 24, 2015
    Assignees: Universite de Bordeaux, Centre Hospitalier Universitaire de Bordeaux
    Inventors: Christine Leaute-Labreze, Eric Dumas De La Roque, Alain Taieb, Jean-Benoit Thambo
  • Publication number: 20150080384
    Abstract: Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse comprising at least 10% by weight hydroxypropylcellulose; polyethylene oxide; and a disintegrant selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium; wherein the ratio of hydroxypropylcellulose to polyethylene oxide on a weight basis is between about 10:1 and 1:10.
    Type: Application
    Filed: November 24, 2014
    Publication date: March 19, 2015
    Applicant: ACURA PHARMACEUTICALS, INC.
    Inventors: Ronald L. LEECH, Rachelle L. HALL YUNG, Albert W. BRZECZKO
  • Publication number: 20150079185
    Abstract: The invention relates to a method for making composite active particles for use in a pharmaceutical composition for pulmonary administration, the method comprising a milling step in which particles of active material are milled in the presence of particles of an additive material which is suitable for the promotion of the dispersal of the composite active particles upon actuation of an inhaler. The invention also relates to compositions for inhalation prepared by the method.
    Type: Application
    Filed: November 25, 2014
    Publication date: March 19, 2015
    Inventors: JOHN NICHOLAS STANIFORTH, MATTHEW MICHAEL GREEN, DAVID ALEXANDER VODDEN MORTON
  • Publication number: 20150071969
    Abstract: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.
    Type: Application
    Filed: May 21, 2014
    Publication date: March 12, 2015
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Paul MCGLYNN, Roger Bakale, Craig Sturge
  • Publication number: 20150050337
    Abstract: Provided are controlled release pharmaceutical compositions comprising desvenlafaxine oxalate, one or more release rate controlling polymers, and pharmaceutically acceptable excipients.
    Type: Application
    Filed: August 13, 2013
    Publication date: February 19, 2015
    Applicant: GENERIC PARTNERS PTY. LTD
    Inventors: Subrata Kundu, Atul Patil, Nitin Borkar
  • Patent number: 8956662
    Abstract: The invention discloses a pharmaceutical composition comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is for oral administration wherein the composition delivers phenylephrine or a pharmaceutically acceptable salt thereof via absorption in the colon. The pharmaceutical composition comprises a core comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is in a time-dependent, pH-dependent, or colon-specific enzyme-dependent erodible layer that degrades to expose the core to release phenylephrine in the colon. In one preferred embodiment, the erodible layer encases the core. The composition optionally further comprises phenylephrine in the erodible layer or other additional layer(s).
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: February 17, 2015
    Assignee: MSD Consumer Care, Inc.
    Inventors: David Monteith, John O'Mullane, Joseph P. Reo, Robert T. Nowak, Jiansheng Wan, Mohammed A. Kabir, Malaz A. Abutarif, Glenn E. Fritz
  • Patent number: 8946290
    Abstract: Active compound combinations of compounds of group A, particularly opioids such as (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol or a salt thereof with a physiologically tolerated acid, and compounds of group B, particularly anti-muscarine agents such as oxybutynin or a salt thereof with a physiologically tolerated acid suitable for treatment of an increased urge to urinate or urinary incontinence. Related pharmaceutical formulations and methods of treatment of an increased urge to urinate or urinary incontinence are also provided.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: February 3, 2015
    Assignee: Gruenenthal GmbH
    Inventor: Thomas Christoph
  • Patent number: 8946301
    Abstract: Methods and therapeutic compositions are disclosed for treating neurodegenerative disorders and, in particular Amyotrophic Lateral Sclerosis, using sphingosine1-phosphate receptor modulators, such as fingolimod or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: February 3, 2015
    Assignee: ALS Therapy Development Institute
    Inventors: Steven Perrin, John Lincecum, Alan Gill, Fernando Vieira
  • Patent number: 8940796
    Abstract: An oral, aqueous-based, liquid pharmaceutical composition is provided. The composition comprises up to about 45% w/v glycerin and up to about 10% w/v sorbitol wherein the glycerin to sorbitol ratio is about 2:1 to 10:1.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: January 27, 2015
    Assignee: Wyeth LLC
    Inventors: William Bubnis, Stephanie Shield, Amanda Alley
  • Publication number: 20150024046
    Abstract: The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (A), at least one synthetic or natural polymer (C), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (B) and optionally a wax (D), component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.
    Type: Application
    Filed: October 7, 2014
    Publication date: January 22, 2015
    Inventors: Johannes BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU-MARIC
  • Patent number: 8937085
    Abstract: The present invention relates to a pharmaceutical carrier composition and a pharmaceutical composition comprising said pharmaceutical carrier composition. The pharmaceutical composition comprises: (a) at least 20% (w/w) of the composition of a sugar or a sugar alcohol; (b) one or more pharmaceutically acceptable excipients; (c) one or more pharmaceutically active ingredients in their base form; and (d) water up to 100% (w/w). The present pharmaceutical composition is especially resistant against flocculation, clumping and/or precipitation at room temperature during prolonged time-periods such as one or more years.
    Type: Grant
    Filed: February 13, 2008
    Date of Patent: January 20, 2015
    Assignee: Dafra Pharma N.V.
    Inventor: Frans Herwig Jansen
  • Publication number: 20150018293
    Abstract: Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of a immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal.
    Type: Application
    Filed: May 12, 2014
    Publication date: January 15, 2015
    Applicant: NEWMARKET PHARMACEUTICALS LLC
    Inventors: David ROCK, Mark RIDALL
  • Publication number: 20150018358
    Abstract: Embodiments of the present invention are directed to compositions and methods for the treatment of purpura. Preferred compositions comprise an ? adrenergic receptor agonist selected from selective ?1 adrenergic receptor agonist, selective ?2 adrenergic receptor agonist, non-selective ?1/?2 adrenergic receptor agonist, agents with ?2 adrenergic receptor agonist activity and combinations thereof, in a pharmaceutically acceptable carrier in order to treat and improve the cosmetic appearance of hemorrhagic (purpuric) lesions in the skin.
    Type: Application
    Filed: October 2, 2014
    Publication date: January 15, 2015
    Inventors: Stuart D. SHANLER, Andrew ONDO
  • Publication number: 20150011644
    Abstract: A therapeutic composition comprising: a methamphetamine precursor; a gel-forming polymer; an emulsifier with a lipid backbone; a disintegrant; and a surfactant; wherein the ratio of emulsifier to gel-forming polymer on a weight basis is between about 10:1 and 1:10.
    Type: Application
    Filed: July 2, 2014
    Publication date: January 8, 2015
    Inventor: Ronald Leech
  • Patent number: 8920837
    Abstract: The novel sustained release dosage form comprising an active agent and a combination of a non-swelling pH dependent release retardant and a non swelling pH independent release retardant polymer which provides pH-independent drug release for a considerable period of time after administration.
    Type: Grant
    Filed: July 3, 2006
    Date of Patent: December 30, 2014
    Assignee: Rubicon Research Private Limited
    Inventors: Pratibha S. Pilgaonkar, Maharukh T. Rustomjee, Anilkumar S. Gandhi, Paras R. Jain, Atul A. Kelkar